142 related articles for article (PubMed ID: 6580906)
21. Effects of pirarubicin in comparison with epirubicin and doxorubicin on the contractile function in rat isolated cardiac muscles.
Hirano S; Agata N; Iguchi H; Tone H
Gen Pharmacol; 1995 Oct; 26(6):1339-47. PubMed ID: 7590129
[TBL] [Abstract][Full Text] [Related]
22. Effect of doxorubicin on calcium binding sites in guinea-pig heart.
Villani F; Monti E; Piccinini F; Favalli L; Dionigi AR; Lanza E
Biochem Pharmacol; 1986 Apr; 35(7):1203-4. PubMed ID: 3964297
[No Abstract] [Full Text] [Related]
23. Effects of doxorubicin, 4'-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes.
Chan EM; Thomas MJ; Bandy B; Tibbits GF
Can J Physiol Pharmacol; 1996 Aug; 74(8):904-10. PubMed ID: 8960379
[TBL] [Abstract][Full Text] [Related]
24. Reduction of anthracycline cardiotoxicity by amrinone and sulmazole.
Bossa R; Castelli M; Galatulas I; Ninci M
Anticancer Res; 1988; 8(6):1229-32. PubMed ID: 3218957
[TBL] [Abstract][Full Text] [Related]
25. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
Cini-Neri G; Neri B
Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
[TBL] [Abstract][Full Text] [Related]
28. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
29. Decreased sensitivity of neonatal rabbit sarcoplasmic reticulum to anthracycline cardiotoxicity.
Burke BE; Mushlin PS; Cusack BJ; Olson SJ; Gambliel HA; Olson RD
Cardiovasc Toxicol; 2002; 2(1):41-51. PubMed ID: 12189279
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs.
Lehotay DC; Levey BA; Levey GS
Biomed Pharmacother; 1983; 37(7):312-6. PubMed ID: 6141818
[TBL] [Abstract][Full Text] [Related]
31. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.
Lehotay DC; Levey BA; Rogerson BJ; Levey GS
Cancer Treat Rep; 1982 Feb; 66(2):311-6. PubMed ID: 6120040
[TBL] [Abstract][Full Text] [Related]
33. Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rat.
Monti E; Piccinini F; Villani F; Favalli L
Cancer Chemother Pharmacol; 1986; 18(3):289-91. PubMed ID: 3802385
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
Olson RD; Mushlin PS
FASEB J; 1990 Oct; 4(13):3076-86. PubMed ID: 2210154
[TBL] [Abstract][Full Text] [Related]
35. The role of calcium in the negative inotropic effect of lanthanum.
Villani F; Piccinini F; Favalli L
Experientia; 1976 Oct; 32(10):1317-8. PubMed ID: 976451
[TBL] [Abstract][Full Text] [Related]
36. Interaction between doxorubicin and mitomycin C on mortality and myocardial contractility in guinea pig.
Monti E; Bossa R; Galatulas I; Favalli L; Villani F; Piccinini F
Tumori; 1983 Apr; 69(2):113-6. PubMed ID: 6407163
[TBL] [Abstract][Full Text] [Related]
37. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment.
Bottone AE; Voest EE; de Beer EL
Clin Cancer Res; 1998 Apr; 4(4):1031-7. PubMed ID: 9563899
[TBL] [Abstract][Full Text] [Related]
38. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Menna P; Minotti G; Salvatorelli E
Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
40. The influence of doxorubicin and 4'-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II.
Pierściński G; Drzewoski J; Nowak D
Pol J Pharmacol; 1994; 46(1-2):55-9. PubMed ID: 7981772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
